Quanterix, which is developing its proprietary single molecule array (SiMoA) technology for the in-vitro diagnostics and life science research markets, has appointed Martin Madaus as the new chief executive officer (CEO).
Madaus most recently served as CEO, chairman and president of Millipore which was acquired by Merck for $7bn last year.
He also served Roche Diagnostics as North American Operations head, president and CEO.
Quanterix scientific founder David Walt said Martin brings financial and commercial expertise that will be invaluable as the company executes its plan to launch the SiMoA platform.
Quanterix CEO Martin Madaus said he is convinced that the Quanterix platform will help research scientists and clinicians to overcome the limitations of current detection platforms and enable new medical breakthroughs.
"The simplicity and unparalleled sensitivity of the single molecule detection principle will enable us to build a range of products for research and IVD use," Madaus said.
Quanterix’s proprietary SiMoA technology aids researchers in life science to validate low abundance biomolecules from a single droplet of blood to detect disease, diagnose, select therapy and monitor disease.